Li Dan, Liu Wei, Ma Dan, Yun Fengxiang, Li Shu, Liu Fengqi
a Department of Critical Ill in Internal Medicine , First Hospital Affiliated to Harbin Medical University , Harbin , China.
J Invest Surg. 2018 Jun;31(3):236-240. doi: 10.1080/08941939.2017.1284965. Epub 2017 Feb 27.
The pilot study is designed to investigate the effect of continuous thoracic sympathetic block (TSB) on cardiac function, reconstruction, and hemodynamic parameters in patients with heart failure resulting from valvular heart disease.
The cardiac function parameters, including left ventricle ejection fraction (LVEF), left ventricle end-diastole diameter (LVEDD), fractional shortening (FS), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), were measured in 19 patients before and after TSB treatment. The patients were also classified on the basis of NYHA classification system.
4 weeks of TSB administration improved cardiac function in 18 of 19 patients (94.74%). The patients' LVEF, LVEDD, and NT-proBNP were all improved significantly after treatment.
The favorable clinical outcome of TSB administration suggests an alternative treatment for the patients with heart failure caused by valvular dysfunctions.
本初步研究旨在调查持续胸段交感神经阻滞（TSB）对瓣膜性心脏病所致心力衰竭患者心脏功能、重构及血流动力学参数的影响。
在19例患者TSB治疗前后测量其心脏功能参数，包括左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）、缩短分数（FS）和脑钠肽前体N末端（NT-proBNP）。患者还根据纽约心脏协会（NYHA）分级系统进行分类。
19例患者中18例（94.74%）在TSB治疗4周后心脏功能得到改善。治疗后患者的LVEF、LVEDD和NT-proBNP均显著改善。
TSB治疗取得的良好临床效果提示其可为瓣膜功能障碍所致心力衰竭患者提供一种替代治疗方法。
